NO20091045L - 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler - Google Patents

3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler

Info

Publication number: NO20091045L
Authority: NO; Norway
Prior art keywords: hdl cholesterol; angioplasty; pyridinecarboxamide; increasing agents; pyrazinecarboxamide derivatives
Prior art date: 2006-10-04

Application number

NO20091045A

Other languages

English (en)

Norwegian (no)

Inventor

Paul Hebeisen

Stephan Roever

Matthias Heinrich Nettekoven

Ulrike Obst Sander

Mirjana Andjelkovic

Agnes Benardeau

Evelyne Chaput

Constantinos G Panousis

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-04

Filing date

2009-03-10

Publication date

2009-03-31

2009-03-10 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2009-03-31 Publication of NO20091045L publication Critical patent/NO20091045L/no

Links

DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 2
239000003795 chemical substances by application Substances 0.000 title 1
229960003966 nicotinamide Drugs 0.000 title 1
235000005152 nicotinamide Nutrition 0.000 title 1
239000011570 nicotinamide Substances 0.000 title 1
IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical class NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 title 1
238000002399 angioplasty Methods 0.000 abstract 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
239000004131 EU approved raising agent Substances 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
206010063837 Reperfusion injury Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
201000001386 familial hypercholesterolemia Diseases 0.000 abstract 1
235000010855 food raising agent Nutrition 0.000 abstract 1
208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
208000031225 myocardial ischemia Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20091045A 2006-10-04 2009-03-10 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler NO20091045L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06121755		2006-10-04
PCT/EP2007/060094 WO2008040651A1 (en)	2006-10-04	2007-09-24	3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Publications (1)

Publication Number	Publication Date
NO20091045L true NO20091045L (no)	2009-03-31

Family

ID=38740266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091045A NO20091045L (no)	2006-10-04	2009-03-10	3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler

Country Status (14)

Country	Link
US (3)	US20080085906A1 (pt)
EP (2)	EP2074096B1 (pt)
JP (1)	JP2010505789A (pt)
KR (1)	KR101107896B1 (pt)
CN (1)	CN101522626A (pt)
AU (1)	AU2007304365A1 (pt)
BR (1)	BRPI0717845A2 (pt)
CA (1)	CA2664119A1 (pt)
IL (1)	IL197577A0 (pt)
MX (1)	MX2009003222A (pt)
NO (1)	NO20091045L (pt)
RU (1)	RU2454405C2 (pt)
WO (1)	WO2008040651A1 (pt)
ZA (1)	ZA200902353B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0519058A2 (pt)	2004-12-14	2008-12-23	Astrazeneca Ab	composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
AR058562A1 (es)	2005-12-22	2008-02-13	Astrazeneca Ab	Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
MX2008015226A (es)	2006-05-30	2008-12-12	Astrazeneca Ab	Derivados de 1,3,4-oxadiazol como inhibidores de dgat1.
AU2007266796B2 (en)	2006-05-30	2011-02-10	Astrazeneca Ab	Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
US7781593B2 (en) *	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR069802A1 (es)	2007-12-20	2010-02-17	Astrazeneca Ab	Compuestos de carbamoilo como inhibidores de dgat1 190
US7897621B2 (en)	2008-03-31	2011-03-01	Hoffmann-La Roche Inc.	2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
US8088920B2 (en)	2008-03-31	2012-01-03	Hoffmann-La Roche Inc.	3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
KR101712576B1 (ko)	2008-11-10	2017-03-06	버텍스 파마슈티칼스 인코포레이티드	Ａｔｒ 키나제의 억제제로서 유용한 화합물
PL3354650T3 (pl)	2008-12-19	2022-06-13	Vertex Pharmaceuticals Incorporated	Związki przydatne jako inhibitory kinazy atr
US8338441B2 (en) *	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
MX2011014018A (es)	2009-06-19	2012-02-22	Astrazeneca Ab	Pirazincarboxamidas como inhibidores de dgati.
UA107088C2 (xx) *	2009-09-11	2014-11-25		5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
JP2013526540A (ja)	2010-05-12	2013-06-24	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013526538A (ja)	2010-05-12	2013-06-24	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
US8962631B2 (en)	2010-05-12	2015-02-24	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US9096584B2 (en)	2010-05-12	2015-08-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2011143423A2 (en)	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
JP5836367B2 (ja)	2010-05-12	2015-12-24	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼ阻害剤として有用な化合物
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
JP2013529643A (ja)	2010-06-23	2013-07-22	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体
WO2012031817A1 (en) *	2010-09-09	2012-03-15	F. Hoffmann-La Roche Ag	Determination of abca1 protein levels in cells
US8410107B2 (en) *	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) *	2010-10-22	2012-04-26	Pascal Dott	Process for the preparation of nicotinamide derivatives
US8669254B2 (en)	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
CA2832100A1 (en)	2011-04-05	2012-10-11	Vertex Pharmaceuticals Incorporated	Aminopyrazine compounds useful as inhibitors of tra kinase
JP2014522818A (ja)	2011-06-22	2014-09-08	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012178125A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2012178123A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
CA2844865A1 (en) *	2011-09-12	2013-03-21	F. Hoffmann-La Roche Ag	3-pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2844834A1 (en) *	2011-09-12	2013-03-21	F.Hoffmann-La Roche Ag	5-cycloalkyl- or 5-heterocyclyl-nicotinamides
KR20140061518A (ko)	2011-09-12	2014-05-21	에프. 호프만-라 로슈 아게	N-(5-사이클로알킬- 또는 5-헤테로사이클릴-)-피리딘-3-일 카복스아마이드
US8765751B2 (en)	2011-09-30	2014-07-01	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
RU2018147217A (ru)	2011-09-30	2019-01-18	Вертекс Фармасьютикалз Инкорпорейтед	Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
IN2014KN00943A (pt)	2011-09-30	2015-08-21	Vertex Pharma
US8853217B2 (en)	2011-09-30	2014-10-07	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
AU2012315384B2 (en)	2011-09-30	2017-08-10	Vertex Pharmaceuticals Incorporated	Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
US9403808B2 (en) *	2011-10-28	2016-08-02	Hoffmann-La Roche Inc.	Pyrazine derivatives
EP2776429A1 (en)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2013071090A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP2776421A1 (en)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US8841449B2 (en)	2011-11-09	2014-09-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US8841450B2 (en)	2011-11-09	2014-09-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
CN104582795B (zh)	2012-04-05	2018-04-20	沃泰克斯药物股份有限公司	可用作atr激酶抑制剂的化合物及其组合疗法
KR20150044952A (ko) *	2012-08-23	2015-04-27	에프. 호프만-라 로슈 아게	암의 치료를 위한 신규한 페닐-피리딘/피라진 아미드
DK2904406T3 (en)	2012-10-04	2018-06-18	Vertex Pharma	METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en)	2012-10-16	2014-12-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
LT3418281T (lt)	2012-12-07	2021-01-11	Vertex Pharmaceuticals Inc.	Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
AU2014241430B2 (en) *	2013-03-14	2018-04-26	Dart Neuroscience (Cayman) Ltd.	Substituted pyridine and pyrazine compounds as PDE4 inhibitors
WO2014143240A1 (en)	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
HUE046727T2 (hu)	2013-12-06	2020-03-30	Vertex Pharma	Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
ES2777608T3 (es)	2014-06-05	2020-08-05	Vertex Pharma	Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en)	2014-06-17	2021-11-23	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of Chk1 and ATR inhibitors
MX385777B (es) *	2014-12-24	2025-03-04	Lg Chemical Ltd	Derivado de biarilo como agonista de gpr120.
WO2017047602A1 (ja)	2015-09-18	2017-03-23	科研製薬株式会社	ビアリール誘導体及びそれを含有する医薬
US11464774B2 (en)	2015-09-30	2022-10-11	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US11400082B2 (en)	2017-10-30	2022-08-02	Montréal Heart Institute	Methods of treating elevated plasma cholesterol
PL237374B1 (pl) *	2017-11-10	2021-04-06	Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia	Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie
WO2024003259A1 (en) *	2022-06-30	2024-01-04	Bayer Aktiengesellschaft	Tead inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0104330D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
SE0104332D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
EP1641779A1 (en) *	2003-06-18	2006-04-05	AstraZeneca AB	2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
ES2326280T3 (es) *	2005-04-06	2009-10-06	F. Hoffmann-La Roche Ag	Derivados de piridin-3-carboxamida como agonistas inversos de cb1.
WO2007011760A2 (en) *	2005-07-15	2007-01-25	Kalypsys, Inc.	Inhibitors of mitotic kinesin
US7629346B2 (en) *	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) *	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
WO2008040649A2 (en) *	2006-10-04	2008-04-10	F. Hoffmann-La Roche Ag	Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
US8088920B2 (en) *	2008-03-31	2012-01-03	Hoffmann-La Roche Inc.	3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents

2007
- 2007-09-24 EP EP07820501A patent/EP2074096B1/en not_active Not-in-force
- 2007-09-24 KR KR1020097009023A patent/KR101107896B1/ko not_active Expired - Fee Related
- 2007-09-24 RU RU2009116670/04A patent/RU2454405C2/ru not_active IP Right Cessation
- 2007-09-24 WO PCT/EP2007/060094 patent/WO2008040651A1/en not_active Ceased
- 2007-09-24 AU AU2007304365A patent/AU2007304365A1/en not_active Abandoned
- 2007-09-24 MX MX2009003222A patent/MX2009003222A/es active IP Right Grant
- 2007-09-24 CA CA002664119A patent/CA2664119A1/en not_active Abandoned
- 2007-09-24 CN CNA2007800369086A patent/CN101522626A/zh active Pending
- 2007-09-24 JP JP2009530843A patent/JP2010505789A/ja active Pending
- 2007-09-24 EP EP12153000A patent/EP2450350A1/en not_active Withdrawn
- 2007-09-24 BR BRPI0717845-0A patent/BRPI0717845A2/pt not_active IP Right Cessation
- 2007-09-27 US US11/904,425 patent/US20080085906A1/en not_active Abandoned
2009
- 2009-02-06 US US12/366,692 patent/US7812028B2/en not_active Expired - Fee Related
- 2009-03-10 NO NO20091045A patent/NO20091045L/no not_active Application Discontinuation
- 2009-03-12 IL IL197577A patent/IL197577A0/en unknown
- 2009-04-03 ZA ZA200902353A patent/ZA200902353B/xx unknown
2010
- 2010-06-29 US US12/825,374 patent/US8188093B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20090143409A1 (en)	2009-06-04
WO2008040651A1 (en)	2008-04-10
AU2007304365A1 (en)	2008-04-10
JP2010505789A (ja)	2010-02-25
US7812028B2 (en)	2010-10-12
RU2454405C2 (ru)	2012-06-27
EP2074096A1 (en)	2009-07-01
RU2009116670A (ru)	2010-11-10
IL197577A0 (en)	2009-12-24
US20100267745A1 (en)	2010-10-21
MX2009003222A (es)	2009-04-06
CN101522626A (zh)	2009-09-02
BRPI0717845A2 (pt)	2015-06-16
CA2664119A1 (en)	2008-04-10
EP2074096B1 (en)	2012-06-27
KR20090075852A (ko)	2009-07-09
ZA200902353B (en)	2010-04-28
US20080085906A1 (en)	2008-04-10
US8188093B2 (en)	2012-05-29
KR101107896B1 (ko)	2012-01-25
EP2450350A1 (en)	2012-05-09

Legal Events

Date	Code	Title	Description
2014-04-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
MX2009003222A (es)	2009-04-06	Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad.
PH12013502156A1 (en)	2014-01-06	1,3-oxazines as bace1 and/or bace2 inhibitors
IN2012DN00766A (pt)	2015-06-26
EA201391786A1 (ru)	2014-04-30	Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
WO2012104263A3 (en)	2012-09-27	1,4 oxazines as bace1 and/or bace2 inhibitors
MX2013007558A (es)	2013-08-21	1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
IN2012DN03043A (pt)	2015-07-31
PH12013502090A1 (en)	2018-03-21	1,3 oxazines as bace1 and/or bace2 inhibitors
MX2013008213A (es)	2013-08-09	N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
BR112013031510A2 (pt)	2016-12-27	[1,3]oxazinas
EA201391752A1 (ru)	2014-04-30	Спиро-[1,3]-оксазины и спиро-[1,4]-оксазепины в качестве ингибиторов bace1 и/или bace2
MX2013014194A (es)	2014-03-21	1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
EP2571876A4 (en)	2013-12-25	SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
TN2013000285A1 (en)	2015-01-20	Novel heterocyclic derivatives and their use in the treatment of neurological disorders
EA201000365A1 (ru)	2010-10-29	Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
WO2009111700A3 (en)	2010-03-04	Oxadiazoanthracene compounds for the treatment of diabetes
NO20081729L (no)	2008-05-16	Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
WO2007097931A3 (en)	2007-11-22	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EA201270215A1 (ru)	2012-11-30	Apaf-1 ингибиторные соединения
WO2008127682A3 (en)	2009-05-07	Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
MX354173B (es)	2018-02-16	Fluorometil-5,6-dihidro-4h-[1,3]oxazinas.
MY177686A (en)	2020-09-23	Therapeutic agent for dyslipidemia
WO2009030952A3 (en)	2009-05-07	Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
NZ702254A (en)	2016-08-26	5-amino[1,4]thiazines as bace 1 inhibitors
UY27462A1 (es)	2003-04-30	Derivados de quinolina